Tenax Therapeutics (TENX) Liabilities and Shareholders Equity (2011 - 2026)

Tenax Therapeutics has reported Liabilities and Shareholders Equity for 15 years, with the latest figure at $121.7 million in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $121.7 million, up 14.93% year-over-year; the trailing twelve-month figure through Jun 2026 was $451.9 million (up 9.05% YoY), and the FY2025 annual result was $104.2 million, up 7.8% from the prior year.
• Liabilities and Shareholders Equity retreated to $121.7 million in Q2 2026, from $123.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $123.2 million in Q1 2026 and troughed at $3.4 million in Q4 2022.
• A 5-year average of $53.6 million and a median of $14.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity slumped 46.82%; it then jumped 897.06% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.4 million in 2022, then soared by 243.2% to $11.7 million in 2023, then surged by 727.44% to $96.7 million in 2024, then climbed by 7.8% to $104.2 million in 2025, then grew by 16.73% to $121.7 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $121.7 million in Q2 2026, $123.2 million in Q1 2026, and $104.2 million in Q4 2025.